Genmab A (GMAB) Income from Continuing Operations (2018 - 2026)
Genmab A (GMAB) reported Income from Continuing Operations of 74000000.0 for Q1 2026, down 69.67% on a YoY basis from 244000000.0 in Q1 2025, and down 84.65% quarter-over-quarter from 482000000.0 in Q3 2025.
Genmab A (GMAB) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Genmab A has reported Income from Continuing Operations for 6 years, with the latest figure at 74000000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 69.67% year-over-year to 74000000.0; the trailing twelve-month figure through Mar 2026 stood at 1223000000.0 (up 16.14% YoY), and the FY2025 full-year result was 963000000.0, down 15.0% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 74000000.0, down from 482000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 482000000.0 in Q3 2025, with the low at 74000000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 290285714.29 across 3 years, with a median of 253000000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations jumped 90.51% — and 2026, when it sank 69.67%.
- Genmab A's Income from Continuing Operations stood at 253000000.0 in 2024, then soared by 90.51% to 482000000.0 in 2025, then plunged by 84.65% to 74000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 74000000.0 (Q1 2026), 482000000.0 (Q3 2025), and 423000000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 74.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.00 Mn |
| Sep 30, 2025 | 482.00 Mn |
| Jun 30, 2025 | 423.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Sep 30, 2024 | 253.00 Mn |
| Jun 30, 2024 | 307.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |